Braveheart investment buys automated face mask production line
Braveheart Investment Group announced on Friday that Pharm 2 Farm, in which it has a controlling interest, has placed an order for an automated face mask production line, which is expected to be delivered in November and commissioned by the end of December.
The AIM-traded firm said the face mask production line, manufactured in Europe, had the capacity to produce up to five million standard or antiviral face masks per month.
“Conventional surgical type masks typically consist of three layers, with the inner layer acting as a physical barrier to viruses and bacteria,” the Braveheart board said in its statement.
“However, they are only recommended for up to two hours of continual use as this layer can become moist and fail, thereby allowing the virus to penetrate through.
“Pharm 2 Farm has developed a second defensive layer that incorporates its own nanotechnology, which is engineered to kill viruses and bacteria.”
It said that, combining the new active layer with the physical barrier layer, to produce four layer masks, was expected to improve user safety over prolonged use.
The new material was currently undergoing testing, specifically with respect to the time taken to kill viruses, including Covid-19.
Those tests were being undertaken at the University of Nottingham, with results expected by the beginning of October.
“Following a satisfactory outcome of the tests undertaken at the University of Nottingham, it is envisaged that manufacture of the antiviral face masks will commence in the first quarter of 2021.
“In the event that these tests do not provide a satisfactory outcome, the production line will be used to produce conventional surgical type masks, which Pharm 2 Farm believe could still be produced on a profitable basis.”
At 1142 BST, shares in Braveheart Investment Group were down 4.55% at 21p.